Business Wire

CA-PSMF

3.6.2023 07:12:31 CEST | Business Wire | Press release

Share
The Patient Safety Movement Foundation Concludes Its 10th Annual World Patient Safety, Science & Technology Summit

President Bill Clinton, 42nd President of the United States, headlined day two of the 10th Annual World Patient Safety, Science & Technology Summit, presented by the Patient Safety Movement Foundation (PSMF).

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230602005417/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Joe Kiani, founder of the Patient Safety Movement Foundation, discusses efforts to improve patient safety worldwide with former President Bill Clinton at the 10th Annual World Patient Safety, Science & Technology Summit in Newport Beach, California. (Photo: Business Wire)

As a long-time advocate of patient safety, President Clinton spoke of the need to develop what he termed a “culture of conversion,” where more people within healthcare feel empowered to implement proven practices for eliminating preventable harm within hospitals.

“We know enough right now to cut the current problem by half or more,” he said. “One of the biggest problems you have in every big, complicated society is that there’s an incredibly built-in resistance to being the second, third, fourth, or 100th person to do the same thing, even though it’s been proven to work. Which is exactly the reverse of what we should be doing.”

Reflecting on his time in office during the 1990s, President Clinton said that we could learn much from the example of former South African President Nelson Mandela when it comes to uniting people behind a common cause for good.

“Everyone wants to believe they have some piece to add to life’s great puzzle,” he said. “You need converts to do anything big, and we’ve got to get more zealous converts. Nelson Mandela was a genius at this. He was the best I ever saw. He never tried to make people feel bad for what they hadn’t done. He tried to make people feel good about what they could do.”

Having long been a campaigner on the dangers of the opioid epidemic and a supporter of the PSMF since its inception, President Clinton suggested that it is important to focus on collaborating for future good rather than blaming and shaming when it comes to medical errors.

“No one wants to see innocent people die, and very few are hard-hearted enough not to care,” he said. “You don’t have to save everybody; you just have to save everybody that you can.”

Dr. Michael Ramsay, chief executive officer of the PSMF, told the audience that there is much cause for optimism when it comes to meeting the target of zero preventable deaths by 2030. “I think there’s a future now to patient safety,” he said. “I think things are going to start happening remarkably fast. Technology is changing, we’re gathering more data, and we’ve got more and more people involved in this movement.”

Jeremy Hunt, chancellor of the exchequer of the United Kingdom, delivered a video message to the Summit in which he applauded the difference made by the PSMF over the last decade. “We now have the World Health Organization doing an annual World Patient Safety Day, a 10-year plan to reduce preventable deaths, and we had a ministerial summit this year in Montreux in Switzerland with more than 100 countries represented. We’re making great progress, but there’s a lot of work to do. Even one preventable death is too many. We should be aiming for zero.”

Following on from President Clinton’s remarks about creating the right culture for change within healthcare, Anthony Staines, patient safety program director, Fédération des hôpitaux vaudois, Switzerland, described the need to address the failings of implementation science, a topic also addressed in a talk from Francisco Valero-Cuevas, a professor at the University of Southern California.

“There are many prevention and mitigation solutions, but they are only partly and unsystematically applied,” said Staines. “Science has brought us an expanding body of knowledge. The trouble is that it does not reach the patients.”

There were additional talks from Peter Ziese, chief medical officer at Philips, and Michelle Schreiber of the Centers for Medicare & Medicaid Services. Schreiber told the audience that while healthcare throughout the United States has made significant improvements in patient safety, the pandemic illustrated how our systems are still not durable and resilient enough for times of stress, and gaps in care and infrastructure continue to persist.

Mike Durkin and Sanaz Massoumi, chairman and chief operating officer of the PSMF respectively, gave addresses, and panel discussion topics included the media’s role in covering patient safety, opioid safety, and steps that can be taken in the journey to zero harm. Marcelo Ebrard Casaubón, secretary of foreign affairs of Mexico, received the Joe Kiani Humanitarian Award for his work in patient safety.

Finally, Kiani, founder of the PSMF, reflected on a decade of achievement and the path forward. “We started as a grassroots organization, and the grassroots movement has done so much,” he said. “I think our next step is to demand our elected officials to hardwire patient safety into our system and align the incentives so that every hospital puts evidence-based practices in place.”

ABOUT THE PATIENT SAFETY MOVEMENT FOUNDATION

In 2012, Joe Kiani founded the non-profit Patient Safety Movement Foundation (PSMF) to eliminate preventable medical errors in hospitals. His team worked with patient safety experts from around the world to create Actionable Evidence-Based Practices (AEBP) that address the top challenges. The AEBP are available without charge to hospitals online. Hospitals are encouraged to make a formal commitment to ZERO preventable deaths, and healthcare technology companies are asked to sign the Open Data Pledge to share their data so that predictive algorithms that can identify errors before they become fatal can be developed. The Foundation's annual World Patient Safety, Science & Technology Summit brings together all stakeholders, including patients, healthcare providers, medical technology companies, government employers, and private payers. The PSMF was established through the support of the Masimo Foundation for Ethics, Innovation, and Competition in Healthcare. For more information, please visit psmf.org.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230602005417/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incentive Market Set to Surpass $80B by 2030s — IMA Launches Tools to Help the Industry Keep Pace4.5.2026 16:28:00 CEST | Press release

With combined business spend on loyalty, employee recognition, and channel incentives projected to exceed $80 billion by the 2030s, the incentive industry is entering a period of rapid scale and strategic pressure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260422729016/en/ In response, the Incentive Marketing Association (IMA) launched a new suite of resources designed to help incentive professionals navigate an environment that’s becoming more specialized, fragmented, and central to business performance. “It’s not just more money coming in—it’s more complexity,” said Vince Chiofolo, President of the Incentive & Engagement Solution Providers (IESP). “Buyers are demanding programs that evolve fast, integrate deeply, and feel personal at scale. These new tools were built for that.” IMA’s Suite of Tools Includes: New Industry Report — Inside the Incentive Buyer’s Mind Drawn from insights of 50+ program owners, the report f

Tigo Energy Breaks Global Growth Benchmark; Boosts U.S. Energy Feature in Predict+4.5.2026 15:00:00 CEST | Press release

Advanced energy prediction platform adds real-time energy pricing for North American Independent System Operator (ISO) customers, accelerates meters-connected growth. Tigo Energy, Inc. (NASDAQ: TYGO) (“Tigo” or “Company”), a leading provider of intelligent solar and energy solutions, today announced that the Predict+ platform now offers integrated real-time spot market pricing for ISO customers in the United States. Predict+ provides utilities with deep insights into grid demand, renewable generation, and energy market dynamics, enhancing the precision, scalability, and robustness of energy forecasting to up to 97.5% accuracy through machine learning and artificial intelligence. For energy providers, Predict+ helps streamline operations, reduce volatility, and maximize performance. Predict+ empowers utility operators to adapt to real-world demand challenges when balancing renewable and baseload generation sources, particularly during extreme weather events and market disruptions. On th

Airship Announces 2026 Elevate Customer Experience Award Winners4.5.2026 15:00:00 CEST | Press release

Southwest Airlines, The Economist, and OneFootball among brands recognized at Elevate’26 Customer Experience Summit for setting the standard in mobile-first and AI-centered customer experiences Airship, the mobile-first customer experience company, today announced the winners of the 2026 Elevate Customer Experience Awards. Global brand leaders from The Economist, Southwest Airlines, and OneFootball were among those honored at the Elevate’26 Customer Experience Summit. The Elevate Awards spotlight global companies that have developed exceptional mobile-first customer experiences for their customers, created innovative campaigns, leveraged AI agents to reach new levels of productivity, and achieved real business results. "Evolving mobile-first consumer behaviors and unprecedented advancements in AI are driving a seismic shift that is reshaping how brands interact with their customers," said Brett Caine, CEO, Airship. "The 2026 Elevate Award winners aren’t just adapting, they’re leading t

Alnylam to Present New Analyses at Heart Failure 2026 Underscoring Consistent Clinical Profile of Vutrisiran in ATTR-CM4.5.2026 14:30:00 CEST | Press release

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced it will present new data analyses for vutrisiran in patients with the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) at Heart Failure 2026, a scientific congress of the European Society of Cardiology, taking place May 9-12, 2026, in Barcelona, Spain. ATTR-CM is a heterogeneous and rapidly progressive disease, and patients often present with complex clinical profiles. At Heart Failure 2026, Alnylam will present multiple new analyses from the Phase 3 HELIOS-B study of vutrisiran, which continue to support its use as a first-line treatment for patients with ATTR-CM, and further characterize its clinical profile across patients with a high disease burden, and in the context of concomitant therapies. Vutrisiran is the first and only transthyretin (TTR) silencer for ATTR-CM that delivers rapid knockdown of TTR at the source. Additional analyses being pr

Takeda Announces Positive Topline Results from Pivotal Phase 2/3 Clinical Trial of TAK-881 in Primary Immunodeficiency Disease (PID)4.5.2026 14:00:00 CEST | Press release

Investigational TAK-881 was comparable to established HYQVIA while also demonstrating reduced infusion volume and duration for PID patients Takeda (TSE:4502/NYSE:TAK) today announced that TAK-881-3001, a pivotal Phase 2/3 clinical trial in patients with Primary Immunodeficiency Disease (PID), met its primary endpoint, which demonstrated pharmacokinetic (PK) comparability between the investigational TAK-881 [Immune Globulin Subcutaneous (Human), 20% Solution (SCIG 20%) with Recombinant Human Hyaluronidase] and HYQVIA [Immune Globulin Infusion (Human) 10% with Recombinant Human Hyaluronidase]. Additionally, secondary endpoints showed that TAK-881, a SCIG 20% facilitated with hyaluronidase, demonstrated safety, efficacy and tolerability profiles comparable to HYQVIA, an established SCIG 10% facilitated with hyaluronidase. These findings support the potential of TAK-881 to deliver the required immunoglobulin (IG) dose for PID patients in half the volume of HYQVIA, reducing infusion duratio

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye